Introduction {#S1}
============

Colorectal cancer is an important public health problem in the western world ([@R35]) and the third leading cause of cancer-related death in the United States ([@R23]). Chemoprevention by non-steroidal anti-inflammatory drugs (NSAIDs) has received much attention as a very attractive and promising strategy. A number of studies have demonstrated an inverse relationship between the consumption of NSAIDs and colorectal cancer ([@R16]), and thus molecular mechanisms by which NSAIDs affect chemopreventive activity in human colorectal cancer need to be elucidated.

Tolfenamic acid (TA) is a (N-(2-methyl-3-chlorophenyl)-anthranilic acid that shows a pharmacological profile characteristic of NSAIDs. TA has been broadly used for migraines and has shown fewer side effects than other NSAIDs in the upper gastro-intestine ([@R19]). The first study of TA's anti-cancer activity was performed in a pancreatic cancer model ([@R1]). TA treatment inhibited metastasis and tumorigenesis through suppression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR1) ([@R1]; [@R2]). Using human colorectal cancer cells, our group observed that TA stimulates apoptosis and up-regulates the pro-apoptotic protein early growth response-1 (EGR-1), through epithelial-specific Ets-1 (ESE-1)-dependent transcriptional regulation ([@R25]). These data indicate that TA suppresses tumorigenesis through targeting various molecular mechanisms. Because the underlying cellular mechanisms by which TA exerts its effects are only partially understood, the molecular basis of apoptosis induction and the scope of its action in colorectal cancer need to be elucidated.

Activating transcription factor 3 (ATF3) is an ATF/CREB subfamily member, which is characterized by containing the basic region-leucine zipper (b-ZIP) DNA binding domain ([@R18]). ATF3 plays diverse biological roles and the expression of ATF3 is dramatically up-regulated in response to a variety of stress conditions in many different tissues ([@R17]). ATF3 is rapidly induced in cells treated with growth-stimulating factors such as serum and growth factor ([@R22]). ATF3 enhances DNA synthesis in hepatocytes ([@R3]) and involved in serum-induced cell proliferation as a target gene of c-myc ([@R37]). However, ATF3 has a dichotomous role in cancer development and it is likely that pro- or anti-apoptotic mechanism of ATF3 is dependent on cell or tissue context ([@R32]; [@R45]). The expression of ATF3 was repressed in human colorectal tumors compared to normal adjacent tissue ([@R7]). Ectopic expression of ATF3 induced apoptosis ([@R42]) and suppressed growth of colorectal cancer cells ([@R14]) and Ras-stimulated tumorigenesis ([@R28]). In previous studies, our group reported that ATF3 was induced by treatment with anti-tumorigenic compounds including indole-3-carbinol ([@R26]), conjugated linoleic acid ([@R27]), epicatechin ([@R4]; [@R12]), berberine ([@R36]), and phosphoinositide 3-kinase inhibitor ([@R42]).

ATF3 expression is influenced by various cell signaling and transcription factors. ATF3 is a key mediator of Krüppel-like factor 6 (KLF6)-induced apoptosis in prostate cancer cells ([@R21]) and mediates cyclooxygenase inhibitor-stimulated anti-invasive activity in human colorectal cancer ([@R8]). ATF3 directly enhances p53 activation ([@R44]) and stabilize p53 protein ([@R43]) as well as down-regulates cyclin D1 ([@R28]) and matrix metalloproteinase-2 expression ([@R11]). ATF3 also plays a crucial role in REIC/Dkk-3-induced apoptosis and down-regulation of inhibition of differentiation-1. ([@R24]). Overexpression of ATF3 prolonged the half-life of p73 by inhibiting its ubiquitination and thereby enhancing its transactivation and proapoptotic activities ([@R33]). ATF3 suppresses Toll-like receptor-mediated pathways ([@R38]) and directly represses nuclear factor erythroid-derived 2-related factor 2 (Nrf2) pathways ([@R9]). Thus, overexpression of ATF3 negatively regulates tumorigenic pathways through multiple mechanisms, although there are contradictory results in the literature.

In the present study, we investigated the transcriptional mechanism and biological significance of ATF3 expression in response to TA-activated apoptosis in human colorectal cancer model. Here, we report that ATF2 acts as a mediator in activation of the ATF3 gene by TA via MAPK-dependent pathways.

Materials and Methods {#S2}
=====================

Materials {#S3}
---------

Human cancer cell lines (HCT-116, HT-29, LoVo, and SW480) and other cancer cell lines (A549, MCF-7, PC-3, and Spccy1) were purchased from American Type Culture Collection (Manassas, VA). Culture media were purchase from the followings; McCoy's 5A (Bio Whittaker, Rockland ME), RPMI1640 (Mediatech, Herndon, VA), Ham's F-12 (HyClone, Logan, UT), and DMEM (Invitrogen, Carlsbad, CA). Tolfenamic acid was purchased from Cayman Chemical (Ann Arbor, Michigan), and SB203580, U0126, PD98059, and SP600125 were purchased from Calbiochem (San Diego, CA). Antibodies for ATF3, ATF2, phospho-ERK, ERK, actin and siRNA for ATF3 and ATF2 were purchased from Santa Cruz (Santa Cruz, CA). Antibodies for PARP, phospho-JNK, JNK, phospho-p38MAPK, p38MAPK, and phospho-ATF2 (Thr71) were purchased from Cell Signaling (Beverly, MA). All chemicals were purchased from Fisher Scientific (Pittsburgh, PA), unless otherwise specified.

Cell culture {#S4}
------------

HCT-116 and HT-29 cells were maintained in McCoy's 5A medium. SW480 cells were maintained in RPMI1640. LoVo, A549 and PC-3 cells were maintained in Ham's F-12. MCF-7 and Spccy1 cells were maintained in DMEM. All culture media was supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin.

Promoters {#S5}
---------

Human ATF3 promoter constructs (pATF3-1850/+34 and pATF3-84/+34) were generously provided by Dr. S. Kitajima (Tokyo Medical and Dental University, Tokyo, Japan) and pATF3-1420/+34, pATF3-718/+34, and pATF3-514/+34 were produced from pATF3-1850/+34 using serial deletion ([@R12]). The internal deletion or point mutation constructs of the ATF3 promoter were constructed from wild type pATF3-84/+34 using the QuikChange II mutagenesis kit (Stratagene, La Jolla, CA) with indicated primers ([Table 1](#T1){ref-type="table"}).

Expression vectors {#S6}
------------------

Full-length C/EBPα, C/EBPδ, CHOP, GATA5, and NF-IL3 cDNAs were amplified from human lung cDNA (Clontech, Mountain View, CA) using ReadyMix Taq polymerase (Sigma, St. Louis, MO) with indicated primers ([Table 2](#T2){ref-type="table"}). PCR was performed for 30 cycles at 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min. PCR product of C/EBPα, C/EBPδ, CHOP, GATA5, and NF-IL3 were sub-cloned into pcDNA3.1/V5/His TOPO vector (Invitrogen, Carlsbad, CA) to generate the V5-His-tagged clones. For C/EBPβ expression vector, pOTB7 vector containing full length C/EBPβ cDNA (Open Biosystems, Huntsville, AL) were digested using EcoRI and Xho I and sub-cloned into pcDNA3.1 (Invitrogen) to generate pcDNA3.1/C/EBPβ. The pCG-ATF3 expression construct was generously provided by Dr. T. Hai (Ohio State University, Columbus, OH). The ATF2 expression vector (pEBG2T-GST-ATF2-6His) and CREB expression vector were kindly provided by Dr. Philip Cohen (University of Dundee, Scotland, UK) and Dr. Joo-Heon Yoon (Yonsei University, Seoul, Korea), respectively. The wild type and dominant negative construct of ERK2 were kindly provided by Dr. Melanie Cobb (University of Texas Southwestern, Dallas, TX). The wild type and dominant negative construct of p38 MAPK was previously described ([@R20]).

Caspase 3/7 enzyme activity {#S7}
---------------------------

Enzyme activity of capsapse 3/7 was analyzed using Apo-ONE Homogeneous Caspase-Glo 3/7 Assay kit (Promega, Madison, WI) according to the manufacturer's protocol. The cells were harvested with RIPA buffer containing protease inhibitors, and the same volume of caspase-Glo 3/7 reagent was added to the cell lysates (50 µg protein) in 96-well plates and incubated at room temperature in the dark for 1h. The luminescence was measured using a FLX800 microplate reader (BioTek, Winooski, VT).

Transient transfections {#S8}
-----------------------

Transient transfections were performed using Lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. HCT-116 cells were plated in 12-well plates at the concentration of 2×10^5^cells/well. The next day, plasmid mixtures containing 0.5 µg of ATF3 promoter linked to luciferase and 0.05 µg of pRL-null vector were transfected for 5 h and rescued with fresh media for 24 h. The transfected cells were exposed to DMSO or 30 µM of TA for 24 h. The cells were harvested in 1X luciferase lysis buffer, and luciferase activity was normalized to the pRL-null luciferase activity using a dual luciferase assay kit (Promega, Madison, WI). For the co-transfection experiment, 0.25 µg of ATF3 promoter and 0.25 µg of expression vectors were co-transfected with 0.05 µg of pRL-null vector as described above.

Isolation of RNA and semi-quantitative RTPCR {#S9}
--------------------------------------------

Total RNA was prepared using a RNA isolation kit (Eppendorf, Hamburg, Germany). Total RNA (1 µg) was reverse-transcribed with the iScript cDNA kit (BioRad, Hercules, CA) according to the manufacturer's instruction. PCR was carried out using ReadyMix Taq polymerase (Sigma) with primers for human ATF3 and GAPDH as follows: ATF3: forward 5'-gtttgaggattttgctaacctgac-3', and reverse 5'-agctgcaatcttatttctttctcgt-3'; GAPDH: forward 5'- gggctgcttttaactctggt-3', and reverse 5'- tggcaggtttttctagacgg-3'.

Western analysis {#S10}
----------------

Cells were washed with PBS and cell lysates were isolated in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitors (1 mM PMSF, 5 µg/ml aprotinin, 5 µg/ml leupeptin) and phosphatase inhibitors (1 mM Na~3~VO~4~, 1 mM NaF) and centrifuged at 10,000×*g* for 5 min at 4°C. Protein concentration was determined by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL) using bovine serum albumin (BSA) as the standard. The proteins were separated on SDS-PAGE and transferred to nitrocellulose membranes (Osmonics, Minnetonka, MN). The membranes were incubated with a specific primary antiserum in TBS containing 0.05% Tween 20 (TSB-T) and 5% nonfat dry milk at 4°C overnight. After three washes with TBS-T, the blots were incubated with peroxidase-conjugated IgG for 1 h at room temperature, visualized using ECL (Amersham Biosciences, Piscataway, NJ) and quantified by Scion Image Software (Scion Corp., Frederick, MD).

Electrophoretic mobility shift assay (EMSA) {#S11}
-------------------------------------------

Nuclear extracts were prepared by the manufacturer's protocols (Active Motif, Carlsbad, CA). Oligonucleotide probes were end-labeled with biotin using the following sequences: 5\'-agggg[tgatgcaa]{.ul}cgctctcagggg[tgatgcaa]{.ul}cgctctc-3\'. Nuclear protein (5 µg) was incubated with biotin-labeled oligonucleotide probes (100 nM) and 1X binding buffer (Promega, Madison, WI) at room temperature for 20 min. For competition assay, nuclear extracts were preincubated with the unlabeled oligonucleotide (10x or 100x) for 10 min. For supershift assay, nuclear extracts were preincubated with antibodies for phosphor-ATF2 or ATF2 for 10 min prior to binding reactions. DNA-protein complexes were resolved by 5% nondenaturing polyacrylamide gel and developed using the protocol of LightShift Chemiluminescent EMSA kit (Pierce, Rockford, IL).

Statistical analysis {#S12}
--------------------

Statistical analysis was performed with Student's unpaired *t* test, with statistical significance set at \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.

Results {#S13}
=======

TA induced ATF3 expression in human colorectal cancer and other cancer cells {#S14}
----------------------------------------------------------------------------

A number of studies indicate that NSAIDs prevent or suppress tumor development in human colorectal cancer ([@R16]). To observe which NSAIDs induce ATF3 expression, we treated HCT-116 cells for 24 h with 30 µM of various NSAIDs: conventional (diclofenac, ibuprofen, aspirin, tolfenamic acid, naproxen) and COX-2 selective (SC-236, DFU, celecoxib) or COX-1 selective (SC-560). As a result, TA and celecoxib increased ATF3 expression ([Fig. 1A](#F1){ref-type="fig"}). Sulindac sulfide also increased ATF3 expression in these cells (data not shown). The level of ATF3 protein dramatically rose in the cells treated with 20 µM TA for 24 h, and ATF3 mRNA increased in a dose-dependent manner ([Fig. 1B](#F1){ref-type="fig"}). We also tested ATF3 expression in other colorectal or types of cancer cells ([Fig. 1C and D](#F1){ref-type="fig"}, ). The increased ATF3 expression was observed in HT-29, LoVo and SW480 cells in different concentrations, indicating that ATF3 induction by TA is observed in other colorectal cancer cells. TA also induced ATF3 expression in lung (A549) and prostate (PC-3) cancer cells, but not in breast (MCF-7) and head and neck (Spccy1) cancer cells. It is notable that basal expression of ATF3 is very high in Spccy1 cells.

ATF3 mediated TA-induced apoptosis {#S15}
----------------------------------

Previously, we reported that human colorectal cancer cells treated with TA increased apoptosis in dose-dependent manner ([@R25]). To see whether ATF3 expression affects apoptosis, enzyme activity of caspase 3/7 was measured in empty- (CONT) or ATF3 expression vector (pCG-ATF3)-transfected cells. As shown in [Fig. 2A](#F2){ref-type="fig"}, overexpression of ATF3 increased caspase 3/7 activity, indicating that ATF3 is one of pivotal genes in the pathway of apoptosis. Next, to investigate whether TA-induced apoptosis is associated with ATF3 expression, the cells were transfected with ATF3 siRNA, and PARP cleavage ([Fig. 2B](#F2){ref-type="fig"}) and capsapase activity ([Fig. 2C](#F2){ref-type="fig"}) were measured. As a result, knockdown of ATF3 significantly suppressed PARP cleavage and enzyme activity, suggesting that ATF3 at least partially plays a significant role in apoptosis induced by TA.

Effect of TA on ATF3 gene promoter activity {#S16}
-------------------------------------------

To investigate whether TA affects transcriptional regulation of the *ATF3* gene, promoter activity was measured using five serial deletion constructs (pATF3-1850/+34, pATF3-1420/+34, pATF3-718/+34, pATF3-514/+34 and pATF3-84/+34) ([@R10]). The promoters were transfected into HCT-116 cells and treated with 30 µM of TA for 24 h. As shown in [Fig. 3A](#F3){ref-type="fig"}, TA treatment resulted in a dramatic increase of promoter activity, and fold inductions of luciferase activities were 7.7, 6.1, 6.2, 6.9, and 4.8 in pATF3-1850/+34, pATF3-1420/+34, pATF3-718/+34, pATF3-514/+34 and pATF3-84/+34-transfected cells, respectively, whereas fold induction of luciferase in empty vector-transfected cells was 1.4. These data indicate that the −84 and +34 region of promoter is responsible for TA's effects. To identify potential regulatory *cis*-acting elements that mediate the stimulatory effects of TA, the TFSEARCH Program was used to search for regions of conserved transcription factor binding site within the −84 and +34 region. The ATF3 gene promoter (pATF3-84/+34) contained multiple potential transcription factor-binding sites including IL-6, DTF-1, GCN-4, Sp1, Yi, GATA, ATF/C/EBP, and CBFA-1 ([Fig. 3B](#F3){ref-type="fig"}, upper panel). To confirm the responsible site for the transactivation of ATF3 gene by TA, we constructed eight deletion clones lacking each binding site. HCT-116 cells were transfected with deletion constructs and then exposed to DMSO or TA for 24 h, and subsequently luciferase activity measured. As shown in [Fig. 3B](#F3){ref-type="fig"} (lower panel), transfection of wild type pATF3-84/+34 promoter increased luciferase activity by 5.2-fold whereas transfection of promoter lacking the ATF/C/EBP binding site increased luciferase activity by 1.2-fold, which is the same with basal induction by TA found in cells transfected with empty vector (pGL3-Basic). Internal deletion of IL-6, Sp1, Yi, and CBFA-1 binding sites slightly increased luciferase activity induced by TA. Other deletion constructs did not block TA-induced luciferase activities.

To obtain further evidence that the ATF/C/EBP binding site is responsible for activation of ATF3 transcription by TA, we constructed three point mutation clones replacing two or three nucleotides within the ATF/C/EBP binding site as described in [Fig. 3C](#F3){ref-type="fig"}. Wild type pATF3-84/+34 resulted in 4.7-fold induction of luciferase activity. However, all clones having point mutations in the ATF/C/EBP binding site completely blocked induction of luciferase activity by TA, which is comparable with empty vector-transfected cells. These results indicate that the region spanning −23 and −16 in the promoter of ATF3 plays an essential role in mediating the effect of TA on ATF3 transactivation.

ATF2 mediated ATF3 promoter activation by TA {#S17}
--------------------------------------------

ATF and C/EBP proteins have highly conserved DNA binding domain and share their binding sites. The sequence of the C/EBP binding oligonucleotide (TGATGCAA) closely resembles the consensus sequence of CREB (TCACGTCA) and ATF2/3 (TGACGT(C/A)(G/A)). To investigate which transcription factor is able to affect ATF3 transcription, we measured ATF3 promoter activity after co-transfecting expression vectors including CREB, ATF2, ATF3, C/EBPα, C/EBPδ, C/EBPβ, CHOP (C/EBPζ), GATA5, and NF-IL3. These proteins are able to bind to TGATGCAA site at some extend. Expression of transfected vectors was confirmed by Western blot analysis (data not shown). As shown in [Fig. 4A](#F4){ref-type="fig"}, ATF2 expression caused a dramatic increase of TA-induced luciferase activity, compared with empty vector-transfected cells. Interestingly, expression of CREB, ATF3, C/EBPs and GATA5 significantly decreased TA-induced ATF3 promoter activation, implying that these transcription factors may act as suppressors of the ATF3 gene. ATF2-induced activation of ATF3 promoter activity was completely abolished in the presence of a construct lacking the ATF/C/EBP (−23 to −16), suggesting that ATF2 is necessary for activation of the ATF3 promoter induced by TA ([Fig. 4B](#F4){ref-type="fig"}).

ATF2 bound to the putative ATF/C/EBP binding site in the ATF3 promoter region {#S18}
-----------------------------------------------------------------------------

To examine whether transactivation of the ATF3 gene promoter by the ATF/C/EBP binding site is direct or indirect, we performed electrophoretic mobility shift assays (EMSA) using oligonucleotide probes derived from the ATF3 promoter (−23 to −16). As shown in [Fig. 5A](#F5){ref-type="fig"}, TA caused an induction of formation of the DNA-protein complex. Preincubation of nuclear extracts with 10X or 100X excess unlabeled oligonucleotide abolished the binding activity ([Fig. 5B](#F5){ref-type="fig"}, Lane 3,4) suggesting that the binding protein is sequence specific. To identify the binding protein, supershift assay was performed using antibody against ATF2 and phospho-ATF2. Preincubation of nuclear extracts with a phospho-ATF2-specific antibody resulted in reduction of the protein-DNA complexes, whereas antibody for IgG and ATF2 did not affect the DNA-protein complex, suggesting that the binding protein is phospho-ATF2 ([Fig. 5C](#F5){ref-type="fig"}).

TA induced phosphorylation of ATF2, and knockdown of ATF2 decreased TA-induced ATF3 expression {#S19}
----------------------------------------------------------------------------------------------

Phosphorylation of ATF2 has been shown to be crucial to its ability to bind to cognate DNA sequences and activate gene transcription. Thus, we determined whether TA affects phosphorylation of ATF2. As shown in [Fig. 6A](#F6){ref-type="fig"}, phospho-ATF2 started to increase at 15 min and reached a maximum at 30 min after TA treatment. The induction of ATF2 phosphorylation was followed by high induction of ATF3 expression 2 h after TA treatment. ATF3 mRNA levels began to increase at 1 h and showed time-dependent increase ([Fig. 6B](#F6){ref-type="fig"}). To observe the role of ATF2 in TA-induced ATF3 expression, the cells were transfected with control or ATF2 siRNA and ATF3 expression measured. As shown in [Fig. 6C](#F6){ref-type="fig"}, knockdown of ATF2 significantly ameliorated ATF3 expression by TA, confirming that ATF2 mediates TA-induced ATF3 expression.

Phosphorylation of ATF2 and ATF3 expression was mediated by MAPK pathways {#S20}
-------------------------------------------------------------------------

MAPK signaling is an important pathway affecting ATF2 phosphorylation ([@R34]). So, we examined whether TA treatment affects MAPK pathways. As shown in [Fig. 7A](#F7){ref-type="fig"}, TA enhanced phosphorylation of ERK, JNK, and p38MAPK proteins. To investigate whether these kinases affect TA-induced ATF3 expression, HCT-116 cells were pre-treated with selective inhibitors for p38MAPK, ERK, and JNK and treated with DMSO and 30 µM of TA. As shown in [Fig 7B, C, and D](#F7){ref-type="fig"}, in the presence of inhibitors against p38MAPK (SB203580), ERK (U0126 and PD98059), or JNK kinase (SP600125), TA-induced phosphorylation of ATF2 and expression of ATF3 was inhibited. To confirm the ERK and p38 MAPK dependency of ATF3 expression, we transfected wild type or dominant negative construct of ERK2 and p38 MAPK, and compared TA-induced ATF3 expression. As shown in [Fig. 7E](#F7){ref-type="fig"}, TA-activated ATF3 expression was blocked in the presence of dominant negative kinases of ERK2 and p38. In addition, pre-treatment with inhibitors of ERK, p38MAPK and JNK suppressed ATF3 promoter activity ([Fig. 7F](#F7){ref-type="fig"}). Overall, three major MAPK pathways implicated in TA-induced phosphorylation of ATF2.

Discussion {#S21}
==========

The anti-tumorigenic effects of TA in recent studies have raised an important question regarding the underlying molecular mechanisms. Here, we demonstrate direct evidence that TA enhances apoptosis of human colorectal cancer cells through activation of ATF3 gene transcription via ATF2 phosphorylation in human colorectal cancer cells.

ATF3 markedly accelerated TA-induced apoptosis and knockdown of ATF3 expression ameliorate TA-induced apoptosis ([Fig. 2](#F2){ref-type="fig"}). These data indicate significant relevance of ATF3 gene expression to TA-mediated cancer suppression and a contributory role of ATF3 in caspase 3 and 7-mediated pathways.

Internal deletion and point mutation of the ATF/C/EBP binding site (−23/−16) in the upstream regulatory region of the ATF3 promoter completely blocked the ability of TA to stimulate promoter activity, suggesting that proteins bound to this site mediate the ability of TA to stimulate ATF3 promoter activity. EMSA data showed that phospho-ATF2 is present in complexes bound to the ATF/C/EBP binding site in the ATF3 promoter and this binding is increased by TA. Furthermore, overexpression of ATF2 activates the ability of TA to stimulate gene expression via ATF3 transactivation. On the contrary, knockdown of ATF2 ameliorated TA-induced ATF3 expression. This study indicates that ATF2 directly regulates ATF3 gene expression induced by TA.

ATF2, another member of the ATF/CREB family of basic region-leucine zipper protein, plays an important role in the cellular stress response ([@R29]). ATF2 expression has been associated with maintenance of cancer cell phenotype. ATF2 directly targets genes such as c-jun, cyclins, TNFα, TGFβ, and DNA polymerase b, which are known to play important roles in the stress response, immune response, cell growth and differentiation ([@R6]). However, other studies demonstrate anti-proliferative or apoptotic role of ATF2. Heterozygous Atf-2 mutant mice *a*re highly prone to mammary tumors ([@R31]), and ATF2 plays significant role in hypoxia-induced apoptosis and suppresses development of mammary tumors ([@R31]). Suppression of mammary tumors by ATF2 is associated with activation of tumor suppressor genes Maspin and GADD45a ([@R30]). In keratinocytes, the loss of ATF2 promotes the tumor formation, suggesting a tumor suppressor role of ATF2 in skin ([@R5]). Genetic variants of the ATF-2 gene were also detected in 5 of the 46 (10.6%) lung cancers ([@R40]). Further, constitutively nuclear-localized ATF2 suppressed ionizing radiation-induced prostate cancer progression ([@R13]). So far, the biological effect of ATF2 expression has not been studied in colorectal cancer models. Although ATF2 expression did not affect apoptosis directly in human colorectal cancer cells (data not shown), it is likely that phosphorylation of ATF2 contributes to enhancement of apoptosis via activation of their target genes such as ATF3. Likewise, activation of signal transduction pathways by TA treatment may result in the phosphorylation of ATF2 and regulation of its activity as suggested previously. In fact, the promising anticancer agent 3,3'-diindolylmethane (DIM) activates both JNK and p38 pathways, resulting in ATF2 phosphorylation ([@R41]). Thus, selection of the target gene, apoptotic or antiapoptotic, depends on the type of stress signal and the presence of other binding partners.

Interestingly, protein level of ATF2 was abruptly increased at an early time point after TA treatment ([Fig. 6A](#F6){ref-type="fig"}). It is likely that the increase of total protein of ATF2 is associated with its phosphorylation because phosphorylation of ATF2 protects ATF2 from ubiquitination and subsequent degradation ([@R15]).

This study also indicated that TA treatment not only caused activation of p38MAPK and JNK, but also increased phosphorylation of ERK. Although we did not examine the changes of ATF2 Thr^69^ in this study, it has been shown that p38MAPK phosphorylates ATF2 on Thr^69^ and Thr^71^ residues. The ability of ATF2 to bind to cognate DNA sequence and activate its target gene depends on the phosphorylation of ATF2. The current data show that phosphorylation of ATF2 by TA is positively regulated by the p38MAPK, ERK, and JNK pathways, which subsequently modulate transcriptional activity of ATF3. This highlights a new role for the kinase pathways in the control of cell growth and apoptosis initiated by TA.

One interesting finding of this study is that overexpression of ATF3, all C/EBPs, CREB and GATA5 suppressed TA-induced ATF3 transactivation ([Fig. 4A](#F4){ref-type="fig"}). This is consistent with data that ATF3 auto-represses itself transcriptionally through the same ATF binding site we indicated ([@R39]). Although it is unclear how those transcription factors repress ATF3 transactivation, we may speculate that activation of ATF2 by phosphorylation sequesters inhibitory promoter activity by other bZIP proteins.

In conclusion, the current study provides information on the molecular mechanism of anti-tumorigenic activity by TA. MAPK pathways influence TA-induced phosphorylation of ATF2 and subsequently activate ATF3 expression. The resulting ATF3 activation induces apoptosis in human colon cancer cells ([Fig. 7G](#F7){ref-type="fig"}).
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![Induction of ATF3 expression in tolfenamic acid (TA)-treated cancer cells\
**(A)** HCT-116 cells were treated with various NSAIDs for 24 h at 30 µM. Total cell lysates were harvested and subsequently Western blot analysis was performed for ATF3 and actin. **(B)** The cells were treated with 0, 1, 5, 10, 20, 30, and 50 µM of TA for 24 h and Western blot was performed for ATF3 and actin (upper panel). The cells were treated with 0, 5, 10, 20, 30, and 50 µM of TA for 24 h and semiquantatitive RTPCR was performed for ATF3 and GAPDH (lower panel). **(C)** Other human colorectal cancer cells (HT-29, LoVo and SW480) were treated with 0, 10, 20 and 30 µM of TA for 24 h. **(D)** Lung (A549), breast (MCF-7), prostate (PC-3), and head and neck (Spccy1) cancer cells were treated with 0, 20, and 30 µM of TA for 24 h.](nihms206667f1){#F1}

![Role of ATF3 expression in TA-induced apoptosis\
**(A)** pCG-ATF3 expression vector was transfected into cells using Lipofectamine and then the cells were treated with 30 µM of TA for 24 h. Caspase 3/7 enzyme activity was measured as described in Materials and Methods. The graph represents of three independent experiments. **(B)** HCT-116 cells were transfected with control siRNA (100 nM) or ATF3 siRNA (100 nM) for 24 h using a TransIT-TKO transfection reagent and then treated with 30 µM of TA for 24 h. Western blot analysis was performed for ATF3, PARP, and actin (upper panel). Data from three independent experiments were densitometrically analysed using Scion Image (Scion Corporation, Frederick, MD) and cleaved PARP versus actin was quantified and expressed as fold induction (Lower panel). **(C)** After transfection with control or ATF3 siRNA as described in (B), caspase 3/7 enzyme activity was measured. The data represent mean ± SD from three independent experiments.](nihms206667f2){#F2}

![ATF3 promoter assay in TA-treated HCT-116 cells\
**(A)** Five deletion ATF3 promoter constructs (0.5 µg) were co-transfected with pRL-null vector (0.05 µg) into HCT-116 cells. The cells were treated with DMSO or 30 µM of TA for 24 h and luciferase activity was measured. Fold induction refers to ratio of luciferase activity of TA-treated cells compared to DMSO-treated cells. \*\*\*, P \< 0.001 versus empty (pGL3 basic) vector-transfected cells. The data represent mean ± SD from three independent experiments. **(B)** Upper panel: the putative transcription binding sites within the −84 to +34 region in the ATF3 promoter. The underlines represent the binding sites of the indicated transcription factors which is used for construction of internal deletion clones. Lower panel: each internal deletion clone of pATF3-84/+34 (0.5 µg) was co-transfected with pRL-null vector (0.05 µg) into the cells and then treated with 30 µM of TA for 24 h. The open ovals in the promoter represent the binding site that is internally deleted. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus wild type (WT)-transfected cells. The data represent mean ± SD from three independent experiments. **(C)** The pATF3-84/+34 construct was point-mutated as described in Materials and Methods. Each mutant clone (0.5 µg) was co-transfected with pRL-null vector (0.05 µg) into the cells and then treated with 30 µM of TA for 24 h. \*\*\*, P \< 0.001 versus wild type (WT)-transfected cells. The data represent mean ± SD from three independent experiments.](nihms206667f3){#F3}

![A role of ATF2 in TA-induced ATF3 transactivation\
**(A)** pATF3-84/+34 (0.5 µg) and pRL-null vector (0.05 µg) were co-transfected into cells with indicated expression vector and then treated with 30 µM of TA for 24 h. \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus empty vector-transfected cells. The data represent mean ± SD from three independent experiments. **(B)** HCT-116 cells were co-transfected with wild type pATF3-84/+34 or internal deletion clone lacking the ATF/C/EBP binding site (pATF3-84/+34Δ−23/−16) in the presence of empty (E) or ATF2 expression vector. Then, the cells were treated with 30 µM of TA for 24 h. The results are presented as the means ± S.D. of three independent transfections. The overexpression of ATF2 was confirmed by Western analysis using ATF2 antibody.](nihms206667f4){#F4}

![Binding of ATF2 to the ATF3 promoter\
**(A)** Nuclear extract protein (5 µg) were prepared and incubated with biotin-labeled oligonucleotide containing ATF/C/EBP binding sites (−23/−16) as described in Materials and Methods. Oligonucleotide probes contained the following sequences: 5\'- agggg[tgatgcaa]{.ul}cgctctcagggg[tgatgcaa]{.ul}cgctctc-3\'. Specific protein-DNA complexes are indicated by arrows. **(B)** Nuclear extract protein from TA-treated cells was preincubated with a 10- or 100-fold excess of unlabeled oligonucleotide for 10 min and then incubated with biotin-labeled oligonucleotide and 1X binding buffer (Promega) at room temperature for 20 min. **(C)** Nuclear extract protein was preincubated with specific antibodies against IgG, phospho-ATF2, or ATF2 for 10 min and then incubated with labeled oligonucleotide and 1X binding buffer (Promega) at room temperature for 20 min. DNA-protein complexes were resolved by 5% nondenaturing polyacrylamide gel and developed using the protocol of LightShift Chemiluminescent EMSA kit (Pierce).](nihms206667f5){#F5}

![Increase of ATF2 phosphorylation by TA treatment\
**(A)** Cells were treated with 30 µM of TA for the indicated times, and Western blot was performed for p-ATF2, ATF2, ATF3, and actin. **(B)** The cells were treated with 30 µM of TA for the time indicated and semi-quantative RTPCR was performed for ATF3 and GAPDH. **(C)** The cells were transfected with control siRNA (100 nM) or *ATF2* siRNA (100 nM) for 24 h using a TransIT-TKO transfection reagent and then treated with 30 µM of TA for 2 h. Western blot analysis was performed for ATF2, ATF3, and actin (upper panel). Data from three independent experiments were densitometrically analysed using Scion Image (Scion Corporation, Frederick, MD) and ATF3 versus actin was quantified and expressed as fold induction (Lower panel).](nihms206667f6){#F6}

![Upstream kinase for ATF2 phosphorylation and ATF3 expression\
**(A)** Cells were treated with 30 µM of TA for the indicated times, and Western blot was performed for p-ERK, ERK, p-SAPK/JNK, SAPK/JNK, p-p38, and p38. **(B)** Cells were pre-treated with indicated concentrations of SB203585 and then treated with 30 µM of TA for 2 h. **(C)** Cells were pre-treated with U0126 (10 µM) or PD98059 (40 µM) and then treated with 30 µM of TA for 2 h. **(D)** Cells were pre-treated with SP600125 (30 µM) and then treated with 30 µM of TA for 2 h. **(E)** Cells were transfected with wild type (WT) and dominant negative (DN) mutant construct of ERK2 or p38 kinase and then treated with 30 µM of TA for 2 h. **(F)** Cells were transfected with pATF3-84/+34 and pRL-null vector and pre-treated with indicated concentrations (SB203580, 50 µM; U0126, 10 µM; SP600125, 30 µM) of inhibitors for 30 min and then treated with 30 µM of TA for 24 h. \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus DMSO pretreated cells. **(G)** Proposed mechanism that TA activates ATF3 transcription and apoptosis in human colorectal cancer cells.](nihms206667f7){#F7}

###### 

Primer sequence for internal deletion or point mutation clones of ATF3 promoters

  -------------------------------------------------------------------------------------------------
  Internal\        Forward                                 Reverse
  deletion                                                 
  ---------------- --------------------------------------- ----------------------------------------
  ΔIL-6            5'-gtaagcttgcaacacggagtaaacgaccgc-3'    5'-actccgtgttgcaagcttacttagatcgca-3'

  ΔDTF-1           5'-gcctgggactggagtaaacgac-3'            5'-ggcggcgcggtcgtttactccagtcccagg-3'

  ΔGCN-4           5'-gcctgggactggcaacacgacgaccgcgcc-3'    5'-caggctggcggcgcggtcgtcgtgttgcc-3'

  ΔSp1             5'-gagtaaacgaagcctgagggctataaaagg-3'    5'-ccctcaggcttcgtttactccgtgttgcca-3'

  ΔYi              5'-gagtaaacgaccgcgccgccctataaaagg-3'    5'-gttgcatcaccccttttatagggcggcgcgg-3'

  ΔGATA            5'-gaccgcgccgccagcctgagaaggggtgatg-3'   5'-gagagcgttgcatcaccccttctcaggctgg-3'

  ΔATF/C/EBP       5'-cctgagggctataaaaggggcgctctccaag-3'   5'-cgactgtggcttggagagcgccccttttatag-3'

  ΔCBFA-1          5'-gtgatgcaacgctctccaagagtcgcacgc-3'    5'-gcgcctggctgcgtgcgactcttggagagc-3'

                                                           

  Point mutation   Forward                                 Reverse

                                                           

  mut-22/-19/-18   5'-ctataaaaggggtaatataacgctctccaag-3'   5'-cttggagagcgttatattaccccttttatag-3'

  mut-22/-19       5'-ctataaaaggggtaatacaacgctctccaag-3'   5'-cttggagagcgttgtattaccccttttatag-3'

  mut-19/-18       5'-ctataaaaggggtgatataacgctctccaag-3'   5'-cttggagagcgttatatcaccccttttatag-3'
  -------------------------------------------------------------------------------------------------

###### 

Primer sequence for cloning of expression vectors

  Gene     Forward                               Reverse
  -------- ------------------------------------- --------------------------------
  C/EBPα   5'-tgccgggagaactctaactc-3'            5'-caccggaatctcctagtcctg-3'
  C/EBPδ   5'-aggtgacagcctcgcttg-3'              5'-gtatgggtcgttgctgagtctct-3'
  CHOP     5'-agactgatccaactgcagag-3'            5'-tgcttggtgcagattcacc-3'
  GATA5    5'-ccctgcccgctggtcaagaccacg-3'        5'-gactcagtgggtggtctgttcca-3'
  NF-IL3   5'-ttgttctcctacacacatagatagggtaa-3'   5'-tcagcataatacaaaatggactgc-3'
